Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: Observational longitudinal study

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 390-394

  Metcalfe, C ^a   Tilling, K ^a   Davis, M ^a   Lane, J A ^a   Martin, R M ^a   Kynaston, H ^b   Powell, P ^c   Neal, D E ^d   Hamdy, F ^e   Donovan, J L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Disease management; Kinetics; Prostatic neoplasms; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; COHORT ANALYSIS; EVIDENCE BASED MEDICINE; HUMAN; KINETICS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; VALIDATION PROCESS;

AGED; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 68149168039     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605181     Document Type: Article

References (21)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101
2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson JE (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
3. Bosch JL, Hop WC, Bangma CH, Kirkels WJ, Schroder FH (1995) Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate 27: 241-249
4. Bosch JL, Tilling K, Bohnen AM, Donovan JL (2006) Establishing normal reference ranges for PSA change with age in a population-based study: the Krimpen study. Prostate 66: 335-343
5. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, Noble S, Lane A (2003) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7: 1-88
6. Frankel S, Smith GD, Donovan J, Neal D (2003) Screening for prostate cancer. Lancet 361: 1122-1128
7. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95: 956-960
8. Klotz L (2007) Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol 25: 505-509
9. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, Carroll PR (2007) The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178: 826-831
10. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J (2006) Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 176: 439-449
11. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. National Collaborating Centre for Cancer: Cardiff, 2008
12. Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5: 101-106
13. Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94: 1361-1368
14. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F (2007) Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int 100: 544-551
15. Ross PL, Mahmud S, Stephenson AJ, Souhami L, Tanguay S, Aprikian AG (2004) Variations in PSA doubling time in patients with prostate cancer on 'watchful waiting': value of short-term PSADT determinations. Urology 64: 323-328
16. Schröder FH, de Vries SH, Bangma CH (2003) Watchful waiting in prostate cancer: review and policy proposals. BJU Int 92: 851-859
17. Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, Adolfsson J, Martin RM, Davis M, Fall K, Lane JA, Adami HO, Bill-Axelson A, Johansson JE, Donovan JL (2009) Development of a new method for monitoring PSA changes in men with localised prostate cancer: a comparison of observational cohorts. Eur Urol in press
18. Tilling K, Sterne JA, Wolfe CD (2001) Multilevel growth curve models with covariate effects: application to recovery after stroke. Stat Med 20: 685-704
19. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS Study. Eur Urol 52: 1560-1563
20. van den Bergh RCN, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH (2008) Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer - a review. Eur Urol 54: 505-516
21. Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, Catalona WJ (2006) Comparison of methods for calculating prostate specific antigen velocity. J Urol 176: 2427-2431